

# German Genethics

## Fighting Cancer Hand in Hand





# German Genethics: innovative approach to cancer diagnostics



## Concept

Therapy optimization with the help of **Smart Data**: German Genethics matches the molecular profile of the patient with the worldwide available clinical studies and therapies. This creates a well-founded individual therapy recommendation.

## Product

The product is a recommendation letter for the oncologist that contains a detailed molecular analysis of the tumor in connection with available therapies, clinical studies and drugs. The treating doctor is thus enabled to make an informed and tailored decision for each cancer patient. Excellent scientific expertise, short turn-over time and superior German data protection standards are our guiding principles.

## Particularity

The unique database of German Genethics combines information from science journals and highly specialized molecular biology databases with the latest research results from clinical trials and knowledge about validated therapies. Through complex algorithms this Smart Data solution can classify the DNA characteristics of each individual sample.



## USPs of German Genethics

„Within German Genethics we accelerate the integration of genetic data with the knowledge of leading journals and biological patterns for individualized cancer treatments, **providing a second opinion for the oncologists**”



**Reliable**  
through German  
data security and  
process quality  
standards



**Fast**  
through high  
computing power



**Affordable**  
though guaranteeing a  
favorable price



**Applicable**  
through technology  
transfer



# German Genethics: 3-step-process




## Analyze it!

DNA sequencing:  
GG cancer panel tests  
hundreds of different  
clinically actionable  
genetic variants.




## Empower the decision!

Providing international clinics  
and doctors a solid and safe -  
German Engineered -  
reporting service.



**Spot it!**  
Mapping of oncological  
problems and matching  
them with the knowledge  
database.




Gene	Variant	Pathogenicity	Recommendation
BRCA1	c.5276G>A	Pathogenic	BRCA1-related cancer prevention and treatment
BRCA2	c.4301C>G	Pathogenic	BRCA2-related cancer prevention and treatment
MLH1	c.1043G>A	Pathogenic	MLH1-related cancer prevention and treatment
MUTYH	c.100G>A	Pathogenic	MUTYH-related cancer prevention and treatment



# Molecular profiling of cancer--the future of personalized cancer medicine

Multi-omics Technologies -> Bioinformatics -> Reference Databases

In order to generate a clinically meaningful report, the data coming from the Bioinformatics pipeline is aligned to scientific evidence. This is achieved by connecting specific Oncology knowledge-sets:



Registry data aggregated and integrated from

- ClinicalTrials.gov
- ISRCTN
- EudraCT (European Registry)

Salient features

- 2800** Oncology drugs
- 2730** Tumor types
- 560** genes and variants

**2300**

Drug target relationship/  
drug gene association

**7500+**

Oncology focused  
clinical trials



# Benefits of German Genethics: improvement of the public health

“Personalized medicine is empowering because your personal genetic and other predictive information allows you to take action that is specific for you – rather than the “one size fits all” approach.”  
Francis Collins, MD, PhD, Director, National Institutes of Health



## Benefits to patients

- Increasing opportunity to prevent disease
- Helping avoid adverse drug reactions
- Increasing treatment options
- Pinpointing optimal dosing
- Increasing success rate of the therapies



## Benefits to clinics and oncologists

- More quickly targeting right treatment for a patient
- Expansion to a knowledge-driven institution
- Faster connecting patients to a right clinical trial



## Benefits to health care system

- Saving costs for patients, clinics and insurances through a more efficient healthcare system
- Decreasing society’s socioeconomic burden from disease by increasing the productivity of the citizens and decreasing the number of premature deaths

---

**Upside Potential:** Smart Data for the development of new targeted therapies




## By-product: Big Data analytics

“By 2025 between 100 mill. and 2 bill. human genomes will be sequenced resulting in 2–40 exabytes of genomic data.”\*

### Transforming Big Data into Smart Data

- Data cleaning
- Data structuring & annotation
- Data mining & matching
- Data analysis



### Creating new databases for various economic uses

- Scientific research
- Improvement of cancer therapies
- As basis for the pharmaceutical and nutrition industries for the R&D (e.g. predicting properties of drug molecules, identifying new drug targets, segmenting patients to better target medicines)

---

Expertise: in chemistry, pharmacology, clinical research, genomics, proteomics, cellular and molecular biology, pharmacy, nutrition, toxicology, phytochemistry, applied chemistry, microbiology, immunology, pathology, medicine, cancer, medical nutrition, biotechnology, biochemistry, organic/inorganic/analytical chemistry, bioinformatics and pharmacy



## Contact

Dr. Christian Garbe, Managing Director

---

Frankfurt Biotechnology Innovation  
Center  
Altenhöferallee 3  
60438 Frankfurt am Main / Germany

+49 (0) 69 800 865-0  
[info@fiz-biotech.de](mailto:info@fiz-biotech.de)  
[www.fiz-biotech.de](http://www.fiz-biotech.de)



New.  
German  
Engineering.